Cite
Agbarya A, Sarel I, Ziv-Baran T, et al. Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. Cancers (Basel). 2021;13(16)doi: 10.3390/cancers13164191.
Agbarya, A., Sarel, I., Ziv-Baran, T., Agranat, S., Schwartz, O., Shai, A., Nordheimer, S., Fenig, S., Shechtman, Y., Kozlener, E., Taha, T., Nasrallah, H., Parikh, R., Elkoshi, N., Levy, C., Khoury, R., & Brenner, R. (2021). Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. Cancers, 13(16), . https://doi.org/10.3390/cancers13164191
Agbarya, Abed, et al. "Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs." Cancers vol. 13,16 (2021). doi: https://doi.org/10.3390/cancers13164191
Agbarya A, Sarel I, Ziv-Baran T, Agranat S, Schwartz O, Shai A, Nordheimer S, Fenig S, Shechtman Y, Kozlener E, Taha T, Nasrallah H, Parikh R, Elkoshi N, Levy C, Khoury R, Brenner R. Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. Cancers (Basel). 2021 Aug 20;13(16). doi: 10.3390/cancers13164191. PMID: 34439346; PMCID: PMC8391288.
Copy
Download .nbib